课题基金 / 基金详情

AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY

AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY
与 RADX TECH - OASIS DIAGNOSTICS 签订书面合同,完成验证、批准和生产流程,以扩大产能
批准号:
10505989
负责人:
PAUL SLOWEY
金额:
$767.92万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-08 至 2022-01-07

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Oasis Diagnostics provides a series of innovative tools for standardized saliva acquisition including devices specific for cell free RNA / viral RNA that are ideally suited for COVID-19 testing on difficult saliva specimens. These collection tools [Pure•SAL, Super•SALâ„¢, Micro•SAL and SimplOFy] in particular are agnostic to the test being used and are already being used by many companies developing oral / saliva based tests for COVID-19. Oasis is a small business with under 20 employees and has been requested by companies developing COVID-19 to scale up manufacturing in order to produce volumes in excess of 100,000 Units of these technologies on a daily basis.  In order to be able to meet this goal, Oasis Diagnostics requires additional manpower, equipment and additional resources that it does not have at the present time.  As a result Oasis is seeking funding through the RADx Program to facilitate large scale manufacturing to meet the rapidly growing market for saliva collection technologies
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
  • 批准号:
    82370569
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李啸峰
  • 依托单位:
COVID-19疫情对我国儿童生长发育影响的异质性研究
  • 批准号:
    42371429
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    张知新
  • 依托单位:
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
  • 批准号:
    LQ23A010016
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2023
  • 负责人:
    罗敏
  • 依托单位:
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
  • 批准号:
    82374291
  • 项目类别:
    面上项目
  • 资助金额:
    48万元
  • 批准年份:
    2023
  • 负责人:
    张传涛
  • 依托单位: